British Heart Foundation Randomised Clinical Trial of Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation (BHF PROTECT-TAVI)

During a minimally invasive heart valve replacement, about 3% of patients suffer a stroke when debris from the old valve breaks loose and travels to the brain. This trial tests whether a filter device—placed in the arteries leading to the brain—can catch that debris and prevent those strokes. Aortic stenosis, a narrowing of the heart’s main valve, is common in the elderly and often fatal if untreated. Transcatheter aortic valve implantation (TAVI) offers a faster, less invasive alternative to open-heart surgery, but the risk of stroke remains a major drawback. Strokes during TAVI prolong hospital stays, cause lasting disability, and increase the risk of death. Current practice cannot stop debris from being released, but cerebral embolic protection (CEP) devices may block it before it reaches the brain. If the trial shows CEP devices reduce stroke rates, the change would be immediate and practical: TAVI would become safer for the growing elderly population, potentially shortening recovery times and reducing long-term care needs. This is not fundamental science—it is a direct test of a device already in clinical use, with a clear, measurable outcome. Success would quietly improve a procedure that tens of thousands of people undergo each year.